











































Pharmaceuticals – Portfolio-Übersicht¹ (Stand 15. Februar, 2023)

| Phase 0 ² | Phase I | Phase II | Phase III |
|---|---|--|---|
| DGKalpha-Inh (BAY 2862789)  ● | Elimusertib (ATR-Inhibitor) (BAY 1895344)  ● | Regorafenib (combi Nivolumab) (BAY 734506)  ○ | Copanlisib (PI3K-Inhibitor)  ○ |
| PSMA TAC (BAY 3546828)  ● | AhR-Inhibitor (BAY 2416964)  ● | Asundexian (FXIa-Inhibitor) (BAY 2433334)  ● | Darolutamid (AR-Inhibitor)  ○ |
| PSMA SMOL TAC (BAY 3563254)  ● | mEGFR-Inhibitor (BAY 2927088)  ● | Runcaciguat (sGC-Aktivator) (BAY 1101042)  ● | Finerenone (MR Antagonist)  ○ |
| VVD NRF2-Inh (BAY 3605349)  ● | DGKzeta-Inhibitor (BAY 2965501)  ● | BDKRB1 Receptor Antagonist (BAY 2395840)  ● | Vericiguat (sGC Stimulator)  ○ |
| VVD STAT3-Inh (BAY 3630914)  ● | CCR8-Ab (BAY 3375968)  ● | Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846)  ● | Asundexian (FXIa Inhibitor)  ● |
| SEMA 3a (BAY 3401016)  ● | Herzinsuffizienz-Gentherapie (AB-1002, vormals NAN-101)  ● | Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)  ● | Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ● |
| LGMD2i Gentherapie (LION-101)  ● | sGC-Aktivator (BAY 3283142)  ● | Zabedoseritib (IRAK4-Inh.) (BAY 1834845)  ● | |
| Nächste Generation Leber-MRT (BAY 3393081)  ● | Anti-a2AP (BAY 3018250)  ● | | |
| | P2X4-Antagonist (BAY 2328065)  ● | | |
| | BDKRB1-Rezeptor-Antagonist (BAY 2395840)  ● | | |
| | sGC-Aktivator (BAY 1211163)  ● | | |
| | Bemdaneprocel (Morbus Parkinson-Zelltherapie) (BRT-DA01)  ● | | |
| | Morbus Parkinson-Zelltherapie (AB-1005, vormals AAV2-GDNF-PD)  ● | | |
| | Multisystematrophie-Gentherapie (AB-1005, vormals AAV2-GDNF-MSA)  ● | | |
| | Morbus Pompe-Gentherapie (ACTUS-101)  ● | | |
| | Huntington-Krankheit-Gentherapie (BV-101)  ● | | |
| | GPR84-Antagonist (BAY 3178275)  ● | | |

| Submissions |
|---|
| Darolutamid (AR-Inhibitor) / ADT mit Chemotherapie  ○ |
| // EU, Japan, China: mHSPC |
| Aflibercept 8MG  ○ |
| // EU, US ⁴ : Diabetisches Maculaödem (DME) |
| // EU, US ⁴ : Neovask. altersbedingte Maculadegeneration (nAMD) |

- Onkologie
- Herz-Kreislauf-Erkrankungen
- Frauengesundheit
- Andere

- Neue aktive Substanz
- Life cycle management

-  Antikörper
-  Biologikum
-  Zelltherapie
-  Kontrastmittel
-  Gentherapie
-  Radiotherapie
-  Kleines Molekül

¹ Bayer und Partner gesponsorte Studien, sowie zulassungsrelevante Studien Dritter mit erstem Studienbesuch des ersten Patienten (m/w/d) ² Präklinische ausgewählte Programme auf dem Weg zur IND-Zulassung (Investigational New Drug Application, USA) ³ Durchgeführt von Merck & Co ⁴ US submission made by Regeneron